These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
516 related articles for article (PubMed ID: 33646835)
1. In adults, the Oxford/AstraZeneca vaccine had 70% efficacy against COVID-19 >14 d after the 2nd dose. Chagla Z Ann Intern Med; 2021 Mar; 174(3):JC29. PubMed ID: 33646835 [TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Voysey M; Clemens SAC; Madhi SA; Weckx LY; Folegatti PM; Aley PK; Angus B; Baillie VL; Barnabas SL; Bhorat QE; Bibi S; Briner C; Cicconi P; Collins AM; Colin-Jones R; Cutland CL; Darton TC; Dheda K; Duncan CJA; Emary KRW; Ewer KJ; Fairlie L; Faust SN; Feng S; Ferreira DM; Finn A; Goodman AL; Green CM; Green CA; Heath PT; Hill C; Hill H; Hirsch I; Hodgson SHC; Izu A; Jackson S; Jenkin D; Joe CCD; Kerridge S; Koen A; Kwatra G; Lazarus R; Lawrie AM; Lelliott A; Libri V; Lillie PJ; Mallory R; Mendes AVA; Milan EP; Minassian AM; McGregor A; Morrison H; Mujadidi YF; Nana A; O'Reilly PJ; Padayachee SD; Pittella A; Plested E; Pollock KM; Ramasamy MN; Rhead S; Schwarzbold AV; Singh N; Smith A; Song R; Snape MD; Sprinz E; Sutherland RK; Tarrant R; Thomson EC; Török ME; Toshner M; Turner DPJ; Vekemans J; Villafana TL; Watson MEE; Williams CJ; Douglas AD; Hill AVS; Lambe T; Gilbert SC; Pollard AJ; Lancet; 2021 Jan; 397(10269):99-111. PubMed ID: 33306989 [TBL] [Abstract][Full Text] [Related]
3. In South Africa, a 2-dose Oxford/AZ vaccine did not prevent mild to moderate COVID-19 (cases mainly B.1.351 variant). Irfan N; Chagla Z Ann Intern Med; 2021 May; 174(5):JC50. PubMed ID: 33939483 [TBL] [Abstract][Full Text] [Related]
5. Sustained COVID-19 vaccine willingness after safety concerns over the Oxford-AstraZeneca vaccine. Sønderskov KM; Dinesen PT; Østergaard SD Dan Med J; 2021 Mar; 68(5):. PubMed ID: 33870886 [TBL] [Abstract][Full Text] [Related]
6. Oxford COVID-vaccine paper highlights lingering unknowns about results. Ledford H Nature; 2020 Dec; 588(7838):378-379. PubMed ID: 33293710 [No Abstract] [Full Text] [Related]
7. In high-risk adults, the Moderna vaccine had 94% efficacy against COVID-19 ≥14 d after the 2nd dose. Chagla Z Ann Intern Med; 2021 Mar; 174(3):JC28. PubMed ID: 33646836 [TBL] [Abstract][Full Text] [Related]
8. Acute Transverse Myelitis (ATM):Clinical Review of 43 Patients With COVID-19-Associated ATM and 3 Post-Vaccination ATM Serious Adverse Events With the ChAdOx1 nCoV-19 Vaccine (AZD1222). Román GC; Gracia F; Torres A; Palacios A; Gracia K; Harris D Front Immunol; 2021; 12():653786. PubMed ID: 33981305 [TBL] [Abstract][Full Text] [Related]
9. BioNTech/Pfizer vaccine after Oxford/AZ vaccine increased immune response vs. no second vaccine. Granwehr BP Ann Intern Med; 2021 Nov; 174(11):JC123. PubMed ID: 34724407 [TBL] [Abstract][Full Text] [Related]
10. The BNT162b2 (BioNTech/Pfizer) vaccine had 95% efficacy against COVID-19 ≥7 days after the 2nd dose. Chagla Z Ann Intern Med; 2021 Feb; 174(2):JC15. PubMed ID: 33524290 [TBL] [Abstract][Full Text] [Related]
11. Sweet syndrome after Oxford-AstraZeneca COVID-19 vaccine (AZD1222) in an elderly female. Majid I; Mearaj S Dermatol Ther; 2021 Nov; 34(6):e15146. PubMed ID: 34590397 [TBL] [Abstract][Full Text] [Related]
12. Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom. Pritchard E; Matthews PC; Stoesser N; Eyre DW; Gethings O; Vihta KD; Jones J; House T; VanSteenHouse H; Bell I; Bell JI; Newton JN; Farrar J; Diamond I; Rourke E; Studley R; Crook D; Peto TEA; Walker AS; Pouwels KB Nat Med; 2021 Aug; 27(8):1370-1378. PubMed ID: 34108716 [TBL] [Abstract][Full Text] [Related]
13. DIC-Like Syndrome Following Administration of ChAdOx1 nCov-19 Vaccination. Casucci G; Acanfora D Viruses; 2021 Jun; 13(6):. PubMed ID: 34205940 [TBL] [Abstract][Full Text] [Related]
14. Oxford-AstraZeneca ChAdOx1 COVID-19 Vaccine Does Not Alter Platelet Aggregation. Limami Y; Khalki L; Zaid N; Khyatti M; Turk JE; Ammara M; Mtairag EM; Oudghiri M; Naya A; Taberkant M; Zaid Y Semin Thromb Hemost; 2022 Feb; 48(1):109-111. PubMed ID: 33971677 [No Abstract] [Full Text] [Related]
15. Vaccines and SARS-CoV-2 variants: the urgent need for a correlate of protection. Karim SSA Lancet; 2021 Apr; 397(10281):1263-1264. PubMed ID: 33765410 [No Abstract] [Full Text] [Related]
16. When is it reasonable to extrapolate during a pandemic?: The case of broad UK labeling for AstraZeneca COVID-19 vaccine. Dal-Ré R; Banzi R Eur J Intern Med; 2021 May; 87():1-2. PubMed ID: 33810939 [No Abstract] [Full Text] [Related]
17. Single-dose Oxford-AstraZeneca COVID-19 vaccine followed by a 12-week booster. Hung IFN; Poland GA Lancet; 2021 Mar; 397(10277):854-855. PubMed ID: 33676614 [No Abstract] [Full Text] [Related]
19. Inverse lichen planus post Oxford-AstraZeneca COVID-19 vaccine. Awada B; Abdullah L; Kurban M; Abbas O J Cosmet Dermatol; 2022 Mar; 21(3):883-885. PubMed ID: 34997985 [No Abstract] [Full Text] [Related]
20. The single-dose J&J vaccine had 67% efficacy against moderate to severe-critical COVID-19 at ≥14 d. Sacks HS Ann Intern Med; 2021 Jul; 174(7):JC75. PubMed ID: 34224270 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]